I have worked in the cardiac ICU at Rush for over 28 years. As a bedside nurse my voice has always been heard and changes in patient care come from evidence based practices including nursing input. When I first saw the Kreg Catalyst bed I knew the potential it had in our very sick patient population. I’ve had the privilege to watch the magic of this bed positively impact many patient outcomes time and time again.
Prior to the Covid outbreak in 2020 we used verticalization therapy in certain critically ill patient populations and saw reduced length of stay in direct correlation with use of the Kreg catalyst bed. March of 2020 brought bigger challenges with the Covid-19 arrival in the US. Rush carried the largest load of Illinois sickest patients accepting transfers from all over the state. During this pandemic surge we utilized ECMO in last ditch efforts to save many lives. We realized early on in the pandemic that verticalization therapy used in conjunction with ECMO proved to be a game changer. During the height of the pandemic we had at times 15 patients on ECMO utilizing the Kreg Catalyst bed at different stages of their illness and each time the bed played a huge part in their successful outcomes. Many ECMO centers around the world are scratching their heads trying to figure out how Rush’s Covid ECMO survival rate was greater than 85%, with most of these patients discharging straight home without any supplemental oxygen or LTAC stays.
I am convinced that the Kreg Catalyst bed played a key role in the success and I am proud to have been a part of it.